Moss David J 4

What Happened

• David J. Moss, CEO of Inmune Bio (INMB), exercised 9,014 common stock purchase warrants on July 2, 2026, acquiring 9,014 shares at a reduced exercise price of $1.40 per share for a cash outlay of $12,620.
• The Form 4 also records a related derivative disposition of 9,014 shares reported at $0.13 per share (total $1,127) tied to the exercise event (reported as an in‑the‑money derivative disposition).

Key Details

• Transaction date: 2026-07-02; Form 4 filed: 2026-07-07.
• Purchase: 9,014 shares @ $1.40 = $12,620 (reported as code M — exercised derivative).
• Related disposition: 9,014 shares @ $0.13 = $1,127 (reported as code X — in‑the‑money derivative disposition).
• Footnote: The shares were acquired by exercising 50% of Mr. Moss’s April 2024 warrants under an Inducement Letter that (a) allowed the reduced $1.40 exercise price for these 9,014 warrants and (b) extended the maturity of the remaining 50% of his April 2024 warrants from June 30, 2026 to December 31, 2027.
• Shares owned after the transaction: not specified in the supplied filing details.
• Timeliness: Filed five days after the July 2 transaction (filed July 7); this appears later than the SEC’s usual two-business-day Form 4 deadline.

Context

• This was a cash exercise of warrants (a purchase), which is generally viewed as a direct insider buy rather than a sale. The filing includes both the acquisition entry and a related derivative disposition entry; the footnote clarifies the exercise was part of a negotiated inducement that reduced the exercise price and extended remaining warrant maturities.